Some people still believe that even higher doses, 5,000 or 10,000 IU, may lead to some benefits, but this is not scientifically proven, he added
[2] [10] The choice often depends on patient-specific factors: SGLT2 inhibitors are oral and may be preferred by those averse to injections, whilst GLP-1 receptor agonists may produce greater weight loss and are particularly valuable in established cardiovascular disease
Clinical trials show tirzepatide may produce greater weight loss than semaglutide alone in some patient populations, and the PlexusDx Precision Peptide Genetic Test can help identify whether a patient's genetic profile favors monotherapy or dual-compound treatment
APLB caters especially well to sensitive, reactive, or barrier-compromised skin types
And there are very few people like that
This difference reflects biology, not medication potencyboth deliver weight loss through identical GLP-1 receptor mechanisms